Tratamiento de la Taquicardia Supraventricular

Objectives

This Mexican clinical practice guideline provides an evidence-based national reference for diagnosing, treating and referring people aged over 16 years with supraventricular tachycardia at secondary- and tertiary-care levels. It aims to standardise clinical decision-making, improve care quality, prognosis and quality of life, and support timely referral to services with appropriate treatment capacity.[1][2]It covers classification, causes, clinical presentation, diagnostic investigations, medical, interventional and surgical treatment, complications, prognosis, and referral and counter-referral across the three levels of care.[3][2]

• Improve recognition and documentation of arrhythmias, including assessment of atrial-wave morphology, P:QRS and RP/PR relationships, episode characteristics, triggers and relevant comorbidities.[4]
• Support diagnosis through electrocardiography, echocardiography, imaging, cardiac catheterisation and electrophysiological studies where clinically appropriate.[1][5]
• Deliver comprehensive management for sinus tachycardia, re-entrant tachycardias, focal and multifocal atrial tachycardia, atrial fibrillation and atrial flutter, using medicines, cardioversion, catheter ablation or surgery according to arrhythmia type and clinical status.[1][6][7]
• Prioritise prevention of stroke and systemic thromboembolism in atrial fibrillation and atrial flutter through risk-based antithrombotic management.[8][9][10]
• Promote safe treatment selection by accounting for haemodynamic stability, structural heart disease, heart failure, pre-excitation, contraindications, adverse effects and patient preferences.[11][12][13]
• Facilitate referral to electrophysiology and ablation services for recurrent, symptomatic, poorly tolerated, haemodynamically compromising or drug-refractory arrhythmias, while avoiding unnecessary invasive assessment in simple, infrequent arrhythmias without pre-excitation.[14][15]

Implementation

The guideline is embedded in Mexico’s Master Catalogue of Clinical Practice Guidelines and the Specific Action Programme for Clinical Practice Guidelines, aligned with the Health Sector Programme 2007-2012.[2]It was developed with participation from institutions in the National Health System, coordinated by the National Centre for Health Technology Excellence, with the Mexican Social Security Institute acting as developer, sponsor and funding source.[16][1]Recommendations are intended for cardiology, electrophysiology, haemodynamics, emergency, intensive-care, internal-medicine, congenital-heart-disease and cardiothoracic-surgery personnel.[1]Their application remains subject to clinical judgement, patient needs and preferences, available resources and institutional regulations.[16]

• Use a tiered specialist delivery model, providing emergency, inpatient and cardiology care at secondary and tertiary levels, with referral and counter-referral pathways across all three levels of care.[2]
• Assess haemodynamic stability before acute treatment, using synchronised electrical cardioversion for unstable tachyarrhythmias and a sequential approach for stable narrow-complex tachycardia involving vagal manoeuvres, intravenous adenosine, rate- or rhythm-control medicines, and escalation where needed.[14][7]
• Apply non-pharmacological and pharmacological treatment according to the specific rhythm disorder, including correction of underlying causes in physiological sinus tachycardia and ectopic junctional tachycardia.[17][18]
• Refer eligible patients for electrophysiological assessment or transcatheter ablation when medicines are ineffective, harmful, not preferred, or when defining the arrhythmia mechanism is necessary for treatment selection.[15]
• Use anticoagulation and antiplatelet decisions for atrial fibrillation or flutter according to thromboembolic and bleeding risk, including CHADS2, CHA2DS2-VASc and HAS-BLED assessment where specified.[9][19][20]
• Monitor clinical treatment through electrocardiography, Holter monitoring, exercise assessment, blood-pressure observation during selected intravenous therapies, international normalised ratio monitoring for vitamin K antagonist treatment, and scheduled cardiology follow-up according to arrhythmia and risk.[21][22][13][23]
• Develop recommendations through clinical-question formulation, systematic searches of electronic databases, guideline repositories and manual sources, literature review and evidence grading.[1][3][24]The review considered 21 documentary sources, including selected guidelines, randomised and non-randomised trials, case reports and other sources.[3]
• Grade evidence using source-guideline systems where available, including American College of Cardiology, American Heart Association and European Society of Cardiology classifications, and use the modified Shekelle scale when guideline evidence was unavailable.[25][26][27]
• Validate the guideline through peer review, internal Mexican Social Security Institute review and external review by the National Academy of Medicine; record its registration as IMSS-535-12 and plan updating three to five years after publication.[3]

Governance includes the Mexican Social Security Institute’s Clinical Excellence Division and Coordination of High-Specialty Medical Units, alongside an academic committee responsible for clinical-guideline development, implementation, evaluation and process innovation.[28]National participation also includes the Ministry of Health, social-security institutions, state health services, professional academies, medical faculties, hospitals, quality organisations and health-technology assessment bodies through the National Committee for Clinical Practice Guidelines.[29][30][31]The supplied material does not define programme-level performance indicators, routine implementation reporting, audit arrangements or a dedicated budget beyond identifying the Mexican Social Security Institute as sponsor and funding source.[1][3]

Monitoring & Evaluation

Evaluation is primarily clinical and evidence-based rather than a programme-level performance system. The guideline uses formal evidence grading, clinical assessment, follow-up and treatment-safety monitoring, but does not set out national implementation indicators, routine reporting requirements, surveillance architecture, audit arrangements or institutional accountability procedures.[32][26][27]

• Grade evidence and recommendations using source-guideline systems, including numerical or alphanumerical evidence levels, lettered recommendation strength, the modified Shekelle scale, and American College of Cardiology, American Heart Association and European Society of Cardiology classifications.[32][25][26][27]
• Support guideline development through systematic searches, literature review, grading of evidence, peer-clinician validation, internal review by the Mexican Social Security Institute, and external review by the National Academy of Medicine.[1][3][24][33]
• Update the guideline three to five years after publication; it is registered as IMSS-535-12.[3]
• Assess symptoms in atrial fibrillation and atrial flutter using the European Heart Rhythm Association symptom score, and use CHADS2, CHA2DS2-VASc and HAS-BLED tools to assess thromboembolic and bleeding risks.[22][9][19][34][20]
• Monitor anticoagulation through the international normalised ratio, recognising that values below 2 do not prevent thromboembolism and values above 3 increase bleeding risk.[19]
• Record a 12-lead electrocardiogram at least quarterly during anti-arrhythmic treatment, and consider Holter monitoring to assess rate control, treatment-related bradycardia, exercise-related symptoms and medicine safety.[22][9][13]
• Apply clinical targets for atrial fibrillation or flutter rate control, initially aiming for a resting heart rate below 110 beats per minute and using stricter targets below 80 beats per minute at rest and below 110 beats per minute during moderate exercise when symptoms persist or tachycardiomyopathy develops.[13]
• Undertake six-monthly surveillance without pharmacological treatment for asymptomatic, non-incessant unifocal atrial tachycardia, and monitor adverse effects when combination anti-arrhythmic therapy is used.[35][36]
• Provide follow-up according to arrhythmia and risk: annual cardiology review for low-risk atrial fibrillation, monthly international normalised ratio monitoring for intermediate- or high-risk patients receiving anticoagulation, and monthly review after atrial fibrillation ablation.[23][37]
• Refer persistent or drug-refractory supraventricular tachycardia to third-level electrophysiology services, with electrocardiography, chest radiography, echocardiography, Holter monitoring and pre-operative testing as appropriate.[38]
• Monitor acute treatment safety through haemodynamic assessment and blood-pressure observation during adenosine or verapamil administration, and respond to haemodynamic deterioration with indicated cardioversion.[21][12][14]

Costing & Financing

Cost and financing information is very limited. The Mexican Social Security Institute is identified as the guideline’s sponsor and funding source, while the clinical burden of supraventricular tachycardia is associated with significant treatment costs, longer hospital stays and complications. No monetary budget, allocation, treatment price, resource-mobilisation plan, funding gap or economic evaluation is specified.[1][4][2]

• Identify the Mexican Social Security Institute as the developing organisation, sponsor and funding source for the guideline.[1]
• Recognise that supraventricular tachycardias may generate significant treatment costs and increased hospital length of stay.[4]
• Recognise that costs may also arise from complications occurring in and outside hospital, although no value or costing method is given.[2]
• Require specialist resources for the guideline’s clinical pathways, including electrocardiography, echocardiography, computed tomography, magnetic resonance imaging, cardiac catheterisation, electrophysiology, catheter ablation and cardiac surgery; however, no corresponding resource allocation is specified.[1]
• Refer patients to units able to perform transcatheter ablation when that treatment is unavailable locally, without specifying funding arrangements for referral or specialist care.[35]
• Note that rivaroxaban was not included in the basic medicines list when the guideline was completed, but no procurement, affordability or reimbursement analysis is provided.[39]
• Leave unspecified the costs of medicines, diagnostic tests, hospitalisation, cardioversion, electrophysiological studies, ablation, surgery, follow-up, workforce, equipment and service capacity.[40][41]